03.17.22 EndPoints: Q&A with GreenLight CEO Andrey Zarur Share: Share on Linkedin Share on Twitter Share on Facebook GreenLight Biosciences CEO, Andrey Zarur, is interviewed by Endpoints News. He outlines how he is determined not to repeat the mistakes from the last pandemic and speaks about GreenLight’s latest deal with the Serum Institute. Can you talk to me about how you’ve identified the shingles vaccine as a key area of focus?[Shingles] can be dangerous and is extraordinary painful. [A shingles vaccine] is a huge unmet need, there are billions of people who are at risk of shingles who don’t have a solution, and of course there is no established business model. So we’re focused on a major need that’s likely to affect everybody over the age of 60. Read the full article here. Find out more about how GreenLight manufactures RNA.